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Abstract 
The fine balance between the secretion, composition, volume and turnover of cerebrospinal fluid (CSF) is strictly 
regulated. However, during certain neurological diseases, this balance can be disrupted. A significant disruption to 
the normal CSF circulation can be life threatening, leading to increased intracranial pressure (ICP), and is implicated 
in hydrocephalus, idiopathic intracranial hypertension, brain trauma, brain tumours and stroke. Yet, the exact cellular, 
molecular and physiological mechanisms that contribute to altered hydrodynamic pathways in these diseases are 
poorly defined or hotly debated. The traditional views and concepts of CSF secretion, flow and drainage have been 
challenged, also due to recent findings suggesting more complex mechanisms of brain fluid dynamics than previ-
ously proposed. This review evaluates and summarises current hypotheses of CSF dynamics and presents evidence for 
the role of impaired CSF dynamics in elevated ICP, alongside discussion of the proteins that are potentially involved in 
altered CSF physiology during neurological disease. Undoubtedly CSF secretion, absorption and drainage are impor-
tant aspects of brain fluid homeostasis in maintaining a stable ICP. Traditionally, pharmacological interventions or 
CSF drainage have been used to reduce ICP elevation due to over production of CSF. However, these drugs are used 
only as a temporary solution due to their undesirable side effects. Emerging evidence suggests that pharmacological 
targeting of aquaporins, transient receptor potential vanilloid type 4 (TRPV4), and the  Na+–K+–2Cl− cotransporter 
(NKCC1) merit further investigation as potential targets in neurological diseases involving impaired brain fluid dynam-
ics and elevated ICP.
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Background
Elevation of intracranial pressure (ICP) after a neuro-
logical injury has been reported in numerous conditions 
including hydrocephalus, idiopathic intracranial hyper-
tension  (IIH), oedema, traumatic brain injury  (TBI), 
and stroke [1]. Uncontrolled raised ICP can worsen out-
comes, and several manoeuvres have been proposed to 
mitigate ICP elevations. The deleterious consequences of 
unchecked ICP highlight the importance of maintaining 
ICP homeostasis within the central nervous system 
(CNS). Cerebrospinal fluid (CSF) is an important com-
ponent of maintaining a stable ICP, and disruptions to 
secretion or drainage can lead to ICP elevations [2]. 
However, a cogent review of the involvement of CSF in 
the elevation of ICP in pathologic conditions of the CNS 
is currently lacking.
CSF serves as a protective fluid to the brain and spinal 
cord, cushioning them from mechanical injury, and acts 
to reduce the brain’s effective weight—its actual mass is 
~ 1500 g while the buoyancy provided by CSF reduces its 
net weight to 25–50 g [3]. It serves as a critical mecha-
nism for transporting nutrients and hormones from one 
area to another [3–5]. CSF also plays a role in protein 
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clearance within the CNS by mechanisms hotly debated 
[6–9]. Reduced CSF secretion as a function of aging [1] 
contributes to increased protein aggregation and has 
links to increased beta-amyloid deposition in Alzheimer’s 
disease [10, 11] or phosphorylated tau protein in chronic 
traumatic encephalopathy [12].
The exact mechanisms of CSF secretion, flow and reab-
sorption/drainage are debated; however, it is understood 
that alterations to normal physiology can contribute 
to elevated ICP. The traditional view of CSF drainage is 
that fluid flows from the subarachnoid space through the 
arachnoid villi and drains into the blood of the superior 
sagittal sinus (Fig. 1) [13]. Studies conducted in multiple 
animal species also point to lymphatic drainage of CSF in 
which CSF exits the cranium through the cribriform plate 
and spinal canal to reach the cervical and spinal lymph 
nodes [14–18]. While there is debate about the dynam-
ics of CSF, studies have attempted to elucidate how our 
current hypotheses of CSF physiology may be influenced 
by neurological disorders or injury. Factors influencing 
secretion, flow and drainage are under investigation and 
are relevant in conditions of elevated ICP, as CSF contrib-
utes to the overall pressure of the CNS. An assessment of 
how both ICP and CSF physiology are affected by pathol-
ogy may offer us a potential target for attenuating ICP 
elevations in several conditions of the CNS.
This review aims to examine existing literature—
acknowledging our current understanding of CSF physi-
ology and controversies in the field, while exploring 
how altered secretion and drainage may link to ICP in 
pathology. This will allow us to identify gaps in knowl-
edge and to identify new targets for research within the 
field of CNS injury.
Review
CSF secretion
The choroid plexus as the primary site of CSF secretion
It is estimated that around 80–90% of CSF is secreted 
by the choroid plexus, a highly-vascularised structure 
of epithelial cells located in the ventricles of the brain. 
The epithelial cells surrounding the capillaries compose 
a blood-CSF barrier (BCSFB), which selectively controls 
the movement of solutes and water to regulate the com-
position of CSF [19]. Under normal physiological condi-
tions, the total volume of human CSF is between 150 and 
160 mL [20]. To maintain this volume, CSF secretion and 
drainage must be equal; imbalances to this equilibrium 
will produce an increase in the total fluid content of the 
brain, subsequently causing an elevation in pressure.
Some of the first supporting evidence for the role of the 
choroid plexus in CSF secretion came from Dandy [21], 
which involved the removal of choroid plexus tissue from 
one of the lateral ventricles in a canine. In this study, 
the ventricle containing the remaining choroid plexus 
expanded while the other shrank. Further evidence 
includes experiments by Welch et  al. which demon-
strated a higher haematocrit in the main choroidal vein 
when compared to the main choroidal artery [22, 23]. 
These results implied a movement of fluid and solutes 
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Fig. 1 Conventional view of CSF flow. CSF is produced in the ventricles, beginning in the lateral ventricles, and flows toward the subarachnoid 
space. CSF circulates in the subarachnoid space and drains into the subarachnoid space (via arachnoid projections) and the spinal cord. Arrows 
depict the flow of CSF from the lateral ventricle origin
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(but not blood-borne cells) across the choroid plexus into 
the ventricles, which we now accept as the foundations 
for CSF secretion.
When looking to anatomical clues for the involvement 
of the choroid plexus in CSF secretion, ultrastructure of 
rat choroid plexus epithelial cells, as revealed by elec-
tron microscopy, highly resembles that of typical secre-
tory cells with the presence of: a brush border at the 
apical membrane facing the ventricle, infoldings at the 
basolateral membrane, a high density of mitochondria, 
and a well-developed endoplasmic reticulum [23]. This 
evidence would point to a secretory role of the choroid 
plexus.
Extra‑choroidal fluid secretion
The blood–brain barrier (BBB), formed by endothelial 
cells that line cerebral capillaries connected by tight junc-
tions, is the site of regulated exchange of ions, molecules 
and cells between the blood and the brain [24–26]. Fluid 
transport across the BBB contributes to  the remaining 
10–20% of CSF secretion [27–29]. Interstitial fluid (ISF) 
is produced by fluid secretion across the BBB [28, 30]. 
ISF fills the narrow extracellular space  (ECS) between 
neurons and glia within the parenchyma, while CSF 
occupies the ventricles and subarachnoid space [31]. The 
interaction between ISF and CSF is likely to occur in the 
perivascular spaces (low resistance pathways) surround-
ing the vessels supplying the brain parenchyma through 
bulk flow—which is convective in nature. It was previ-
ously demonstrated that tracers of different sizes were 
cleared from the brain at similar rates despite differing 
diffusion coefficients. These observations imply convec-
tive flow, as they are inconsistent with diffusive flow. It is 
suggested that these tracers, as well as endogenous pro-
teins in the CSF, are distributed around the brain via a 
combination of convective flow in the perivascular spaces 
and diffusion in the tortuous brain ECS [31, 32]. There-
fore, the purpose of this interaction/exchange between 
CSF and ISF is thought to be for the distribution of com-
pounds from one brain region to another, like melatonin 
[33], or for distribution of compounds from the systemic 
circulation, like vitamin C and folate entering the CNS 
via the choroid plexus [31, 34]. CSF can flow into these 
perivascular spaces from the subarachnoid space via 
pores, termed stomata, in the penetrating arteries [35]. 
Here, both fluids interact and may flow back into CSF 
compartments to be drained via the major CSF drainage 
pathways.
Drivers of CSF secretion
Some argue that the generation of CSF is driven by the 
hydrostatic pressure gradient between the blood, cho-
roid plexus epithelial cells, and the ventricles—accord-
ing to Starling’s law of filtration [36]. This means that 
increased ICP, observed in hydrocephalus, may attenuate 
CSF secretion and, conversely, decreased pressure will 
increase CSF secretion. The role of pressure gradients 
in CSF secretion is unclear. If pressure gradients were 
the primary driver of CSF secretion then this would sug-
gest that it is a fluid derivative of serum, produced from 
ultrafiltrate, which is contrasted in various studies of CSF 
regulation in which its ability to independently regulate 
its ionic milieu has been demonstrated—the composition 
of ions in CSF differs significantly from that of plasma 
(Table  1) [37, 38]. Protein content of CSF (0.03 g/dL) is 
lower than that of plasma (7 g/dL), with a CSF/plasma 
ratio of 0.004 [37].
Additionally, alterations in CSF osmolarity have been 
shown to influence water flux across the choroid plexus 
and the BBB [39]. This series of experiments was per-
formed by Klarica et  al. with the aim of disproving this 
traditional view of CSF secretion. However, the influence 
Table 1 CSF composition reported for human, rabbit and dog
a Human CSF values from Ransom [37]
b Rabbit and dog CSF values from Damkier et al. [38]
Solute Humana Rabbitb Dogb
Plasma Conc. CSF Conc. Plasma Conc. CSF Conc. Plasma Conc. CSF Conc.
Na+ (mM/L) 153 147 148 149 155 151
K+ (mM/L) 4.7 2.9 4.3 2.9 4.6 3.0
Ca2+ (mM/L) 1.3 1.1 5.6 2.5 5.7 2.9
Mg2+ (mM/L) 0.6 1.1 2.0 1.7 1.4 2.0
Cl− (mM/L) 110 113 106 130 121 133
HCO3
− (mM/L) 24 22 25 22 26 26
pH 7.40 7.33 7.46 7.27 7.42 7.42
Osmolarity (mOsm) 290 290 298.5 305.2 299.6 305.2
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that altered osmolarity exerts on water flux is not con-
tradictory to the currently accepted hypothesis, and in 
fact, suggests mechanisms of CSF homeostasis that are 
dependent on osmolarity.
While the ISF is continuous with the CSF, the composi-
tion of the former can dramatically differ in ions where 
neuronal activity occurs. We will present one of the 
many mechanisms of focal changes in interstitial ionic 
concentrations that while pronounced in specific extra-
cellular domains have negligible if any effect on overall 
CSF composition. Another example relates to glutamate 
“buffering” at the synapse. Focal glutamate and potas-
sium increases have a profound effect on neuronal firing 
and, if uncontrolled, may cause neurotoxicity. As in the 
case of extracellular potassium regulation (see below) the 
local accumulation of glutamate is not readily measur-
able in ISF/CSF until exaggerated levels are present. The 
movement of water across the BBB and within the brain 
parenchyma follows osmotic gradients. A frequent mis-
perception is that water will enter the brain after blood–
brain barrier disruption alone [40]. However, since the 
osmolarity of brain and serum is roughly identical [41], 
BBB disruption alone may not be sufficient to cause 
oedema. After BBB disruption, potassium moves down 
its concentration gradient from blood into the brain 
resulting in a  K+ concentration that is sufficient to depo-
larize neurons, trigger action potentials and drive repo-
larization further elevating cerebral  K+ levels. Thus  K+ 
homeostasis overlaps with control of water content in the 
brain. However, when the BBB is disrupted, the capillary 
endothelium acts similar to fenestrated capillaries. There-
fore, both osmotic and hydrostatic pressure gradients 
contribute to oedema formation. When this happens, 
ICP and systemic blood pressure, which are determinants 
of hydrostatic pressure, assume an important role [42].
The concentration of potassium in the ISF in the 
mammalian brain increases measurably (3–4  mM) dur-
ing physiologic stimulation, to a larger extent (up to 
12  mM) during seizures or direct synchronous stimu-
lation of afferent pathways, and to exceedingly high 
values (> 30  mM) during anoxia or spreading depres-
sion. In spite of these rapid and large changes in extra-
cellular potassium  (Kout), values return to normal levels 
in a relatively short time. Neuronal excitability is regu-
lated by a complex interaction of excitatory and inhibi-
tory potentials. In pyramidal neurons, depolarising ion 
conductances involved in fast action potential genera-
tion are regulated primarily by the voltage-dependent 
activation/inactivation properties of  Na+ and  K+ chan-
nels; in addition, inward  Na+ and  Ca2+ currents under-
lie the generation of excitatory postsynaptic potentials 
(EPSPs). Termination of these depolarising potentials 
occurs by the voltage- and calcium-dependent activation 
of potassium conductances and by the activation of 
interneurons that release inhibitory neurotransmitters to 
produce inhibitory postsynaptic potentials (IPSPs); the 
latter are mediated by postsynaptic activation of chlo-
ride and potassium currents. Although excitatory events 
are under physiologic conditions, relatively independent 
of modest changes in the driving force for the permeant 
ions, both repolarising potassium and K-IPSP conduct-
ances are critically affected by even modest changes in 
cell resting potential (resting membrane potential, RMP) 
and  [Kout]. Because neuronal RMP depends significantly, 
but not exclusively on  [Kout], the maintenance of homeo-
static control for extracellular potassium plays a crucial 
role in the regulation of neuronal firing. Several mecha-
nisms can explain the rapid clearance of  K+ from the 
ISF: passive diffusion through the ISF, active removal 
by blood flow, and neuronal reuptake. However, these 
mechanisms alone are not fast enough to account for the 
rapid  K+ removal from the ISF seen under experimental 
conditions. Several lines of evidence suggest that brain 
glial cells and more specifically astrocytes, support the 
homeostatic regulation of the neuronal microenviron-
ment. This phenomenon is referred to as spatial buffering 
of extracellular potassium [43–45].
Local control of ion (and water) homeostasis also 
plays a role in determining the extent and velocity of 
cerebrovascular response to neuronal activation. Unlike 
most other organs, the supply of blood (and to some 
extent the venous return) is under indirect neuronal 
control. Whether blood vessels of small calibre (arteri-
oles) receive direct parenchymal neuronal afferent is still 
under debate, but it is increasingly understood that neu-
ronal activity controls local cerebral blood (CBF) flow by 
coupling of neuronal action potentials to vessel diam-
eter by products of neural activity. Several mediators are 
involved, including potassium ions (increased blood flow 
at concentrations below around 10  mM; vasoconstric-
tion at higher potassium levels [46], nitric oxide [47],  H+/
CO2 (e.g., during hypercapnia) [48], or by metabolic sig-
nal (e.g. adenosine or ATP [49, 50]). Dysfunction of any 
or all of these feed-forward mechanisms of neurovascu-
lar coupling are involved in a broad range of neurological 
diseases [51–53].
In addition to local control of CBF, the brain is char-
acterised by an additional “anomaly” when compared 
to peripheral organs. This brain-specific vascular fea-
ture impacts several of the issues currently debated (see 
“glymphatics” below and [30, 31, 54–57]). In the periph-
eral vascular system, the management of fluid move-
ment across the capillary wall is achieved by a synergistic 
combination of transcellular and paracellular pathways. 
Endothelial cell membranes outside of the brain (except 
in the circumventricular organs), in addition to being 
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permeable to water and gases, express aquaporin 1 
(AQP1) water channels [58]. AQP1 is the dominantly 
expressed aquaporin in peripheral endothelial cells. 
However, apart from the endothelium in the kidney, the 
physiological importance of the expression of AQP1 and 
high water permeability remains undetermined [59]. The 
interendothelial clefts, fenestrae, or gaps may be the ana-
tomical substrate of the paracellular pathway.
The role of ion transport in CSF secretion
As alterations to osmolarity alter water flux across the 
choroid plexus, it is no surprise that the transport of ions 
across the BCSFB is important in the secretion process. 
In this process, ions are transported from circulating 
blood into the CSF via their respective transporters while 
water is likely transported by a combination of a transcel-
lular process of uphill water transport (against an osmotic 
gradient) by cotransporters (e.g. glucose transporter 1, 
GLUT1) as proposed by Zeuthen et  al. [60, 61] and via 
the paracellular pathway through tight junctions [62, 63]. 
AQP1, though highly expressed in the apical membrane 
of the choroid plexus, [64] its role in water transport is 
undetermined due to its low expression in the basolateral 
membrane [65]. The transport of  Cl−,  Na+ and  HCO3− 
are important in this process, and pharmacological stud-
ies in which transporters of these ions are blocked have 
provided evidence of their role in the secretion process 
[36, 38]. Although many ion transporters identified in 
the choroid plexus are involved in CSF secretion, the 
movement of  Na+,  HCO3− and  Cl− are some of the most 
important activities in this process [66]. The mechanisms 
driving this transport require consideration of transport-
ers at both the basolateral and the apical membrane.
Ion transport at the choroid plexus epithelial cell is 
depicted in Fig.  2. Briefly, at the basolateral membrane, 
the net movement of  Na+,  HCO3− and  Cl− into the cho-
roid plexus epithelial cell is essential and is driven by the 
 Na+ gradient. This gradient is utilised by  Na+–HCO3− 
cotransporters (NBC) to facilitate the accumulation of 
 HCO3− in the epithelial cell. Carbonic anhydrases within 
the cell also contribute to this accumulation by catalysing 
the production of  HCO3− and  H+ from  H2O and  CO2. 
The resulting  HCO3− gradient drives  Cl− transport into 
the cell by the epithelial anion exchanger 2, AE2. Simul-
taneous to the events at the basolateral membrane, trans-
porters at the apical membrane operate to move  Na+, 
HCO3- Cl-
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Fig. 2 Transepithelial ion transport at the choroid plexus. Movement of solutes from the interstitial space to the intracellular environment via the 
basolateral membrane are shown—AE2 (epithelial anion exchanger 2), AQP1 (aquaporin 1), NBC (sodium bicarbonate coexchanger) and KCC2 
(potassium chloride cotransporter). The movement from the intracellular environment to the CSF in the ventricles via the apical membrane is also 
shown—Na+–K+–ATPase, AQP1, NKCC1 (sodium–potassium-chloride cotransporter 1), NHE (sodium–hydrogen exchanger) and  K+ channel
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 HCO3− and  Cl− between the epithelial cell and the CSF. 
This involves the actions of the  Na+–K+-ATPase pump 
and inward-rectifying anion currents. The involvement 
of  Na+–K+–2Cl− cotransporter (NKCC1), expressed 
in the apical membrane of the choroid plexus is under 
debate; however, some studies have demonstrated that 
bumetanide, an NKCC1 inhibitor, reduces CSF secretion 
at the choroid plexus epithelium [67–70]. Recently, fur-
ther evidence has emerged to support the involvement of 
NKCC1 in CSF secretion independently of osmotic driv-
ing forces. Steffensen et al. [71] have demonstrated using 
both ex  vivo and in  vivo studies on mice that NKCC1 
contributes to approximately half of the CSF production 
by cotransport of water along with its directional trans-
location of ions independently of an osmotic gradient. 
In addition, in a rat model of post-haemorrhagic hydro-
cephalus, NKCC1 was hyper-activated by inflammatory 
markers in the CSF, and caused bumetanide-sensitive 
ventriculomegaly [72]. One study proposes that some 
of the inhibitory actions of bumetanide, a drug thought 
to act on NKCC1 channels, occur through inhibition 
of AQP1 at high concentrations. Using Xenopus lae-
vis oocytes, they demonstrate that a derivative of the 
bumetanide compound, AqB013, can inhibit both AQP1 
and AQP4 channels with high affinity, confirming the 
water channel as the site-of-action by targeted mutagen-
esis [73]. However, a recent study could neither replicate 
the effect on AQP4-mediated osmotic water permeability 
by AqB013 and bumepamine nor the bumetanide’s inhib-
itory action on AQP4 in a rat oocyte assay as reported 
by Migliati et  al. [73]. Yool and colleagues subsequently 
tested the blocking potential of additional bumetanide 
derivatives on AQP1 channel conductance and dem-
onstrated attenuation in cancer cell migration upon 
administration of AqB007 and AqB011 [74]; however, the 
blocking actions of these derivatives on AQP1 have yet 
to be demonstrated by other groups, and therefore, their 
potential actions on CSF secretion remain unknown.
Control of CSF secretion
The involvement of carbonic anhydrase in the CSF 
secretion process has been targeted therapeutically in 
the treatment of hydrocephalus and IIH with the use of 
acetazolamide [75]. It acts as an inhibitor of the sulphon-
amide-sensitive carbonic anhydrases and reduces CSF 
secretion by ~ 50% [76]. This highlights the importance 
of  HCO3− within the choroid plexus epithelium and pro-
vides further evidence of the tissue’s role as an impor-
tant site of CSF secretion. In addition, recent reviews of 
acetazolamide as a pre-operative strategy for reducing 
CSF rhinorrhoea and associated elevated ICP are promis-
ing, further supporting carbonic anhydrase as a target for 
attenuating ICP [77].
Investigations of new therapies to reduce ICP in neu-
rological conditions are ongoing. Recently, exendin-4 was 
studied as a potential modulator of CSF secretion and 
ICP elevation [78]. Exendin-4 is an agonist of the Gluca-
gon-like peptide-1 receptor (GLP-1R), a class B G-pro-
tein coupled receptor, which, upon activation, stimulates 
adenylate cyclase to convert ATP to cAMP. This increase 
in cAMP production increases the activation of protein 
kinase A, which inhibits  Na+-K+-ATPase—an impor-
tant component of CSF secretion at the choroid plexus. 
The authors of this study hypothesised that since GLP-
1R in kidney cells is already utilised as a target to pre-
vent  Na+ transport, it may be targeted in a similar way 
within the choroid plexus to attenuate CSF secretion. 
Using tissue slices, cell culture and animal models of 
hydrocephalus, they showed that acute treatment with 
exendin-4 reduced  Na+–K+-ATPase activity and resulted 
in a reduction of ICP in female hydrocephalus rats. The 
authors propose that as GLP-1R agonists are already used 
in the treatment of diabetes, these drugs could be repur-
posed for targeting conditions of raised ICP.
Aquaporin involvement in CSF secretion
The involvement of aquaporins (AQPs) in fluid produc-
tion within the CNS has long been established [60, 79]. 
They are capable of transporting water, ions and solutes 
across a cell membrane, and therefore, it is likely that 
they are involved in the process of CSF secretion [80]. 
AQP1, 4 and 9 are expressed in the brain, with AQP1 and 
4 being the main contributors to brain fluid homeosta-
sis. AQP4 is primarily located in the astrocyte processes 
and endfeet that are located at key interfaces between the 
brain and major water-containing compartments, such 
as the BBB, and the BCSFB (at the pial and ependymal 
surfaces, and possibly fourth and lateral ventricle cho-
roid plexuses, [65]), signifying the importance of AQP4 
in regulating brain fluid homeostasis [81, 82]. AQP1 is 
mainly expressed in the apical membrane of choroid 
plexus epithelial cells, which suggests a role in CSF secre-
tion. AQPs have the ability to transport water bi-direc-
tionally across cell membranes in response to changes in 
passive osmotic pressure gradients as they have a high 
capacity and greater selectivity for the water molecules. 
For example, the selectivity of these channels allows for 
water to pass through but not acid. AQPs have a narrow 
pathway that is a very tight fit for water, and the mecha-
nism in the pore allows water molecules to pass through 
in a single file with no resistance [80, 83]. This mecha-
nism allows AQPs to rapidly transport water across cell 
membranes. However, several proteins (e.g. NKCC1 
and GLUT1) expressed at the endothelium co-transport 
water independently of osmotic gradients along with 
their substrates (reviewed in [60]). Therefore, although 
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there is evidence to support a role for AQPs in modulat-
ing ISF and CSF circulation, the exact mechanisms and 
the extent of their contribution remain to be investigated.
A role for AQP1 in CSF secretion seems logical when 
considering its high expression in the apical membrane of 
the choroid plexus [64]. Oshio et al. [84] compared cho-
roid plexus water permeability, CSF secretion, and ICP in 
AQP1-null mouse models with wild-type counterparts 
to elucidate the contribution of AQP1 to CSF secretion 
and ICP maintenance. AQP1-null mice showed ~ 20% 
reduction in the rate of CSF secretion when compared to 
wild-type mice, accompanied by ~ 50% decrease in ICP. 
Protein Kinase C activation in both models augmented 
the difference in secretion rates to ~ 25%. The majority 
of the decreased ICP in the AQP1-null mice is explained 
by a drastic reduction in central venous pressure between 
the two groups; however, when this is accounted for, 
the authors ascribe ~ 25% of the ICP drop to reduced 
CSF secretion. These experiments suggest that AQP1 is 
involved in CSF secretion. However, further studies in 
multiple animal species are required before a definitive 
role is assigned to AQP1 in this process.
AQP1 localisation within choroid plexus epithelial cells 
was shown to be altered in a kaolin-induced hydroceph-
alus model of mice, in which there was an increase in 
intracellular vesicle expression of AQP1 coinciding with 
a decrease in apical membrane expression [85]. These 
results indicate a compensatory mechanism employed 
by the epithelium to reduce water flux into the ventri-
cles when there is excessive CSF secretion. Additionally, 
Wang et  al. [85] found a decrease in ventricular size in 
AQP1-deficient mice, suggesting a reduction in CSF 
secretion. Overall, these findings implicate AQP1 at the 
apical membrane in the CSF secretion process, at least 
in part, and offer a potential target for controlling this 
process experimentally and therapeutically to target con-
ditions of excess CSF secretion or elevated ICP. In fact, 
some antagonists of both AQP1 and AQP4 are already 
under investigation for their translational value in condi-
tions in which these channels are implicated—like hydro-
cephalus [86].
CSF flow
From the primary site of secretion in the choroid plexus, 
CSF flows throughout the ventricular system of the 
brain. CSF flows from the lateral ventricles to the third 
ventricle via the foramen of Monro. From here, it flows 
across the cerebral aqueduct of Sylvius to the fourth 
ventricle and onto the subarachnoid space through the 
apertures of Magendie and Luschka [3]. It was previ-
ously assumed that CSF flow was driven by pulsations of 
the choroid plexus and, now, recent research correlates 
CSF flow through the system with both respiration rate 
and, to a lesser degree, heart rate [87]. This correlation 
would observe the bidirectional flow of CSF i.e. rostral 
movement during deep inhalation and caudal movement 
during deep exhalation. However, this correlation is chal-
lenged by multiple other hypotheses such as CSF flow via 
the ‘glymphatic’ system (described below) in which CSF 
moves by convection, and some experiments have dem-
onstrated CSF movement by diffusion [88].
The next step of CSF flow from the subarachnoid space 
to systemic circulation is under investigation. Many 
hypothesise transport of CSF into the blood through the 
superior sagittal sinus, while others argue that CSF drains 
into external lymphatics. The following section will dis-
cuss the available evidence of CSF drainage presented for 
both direct drainage into the blood and the role of extrac-
ranial lymphatics.
CSF drainage
Arachnoid villi
The classical perception of CSF drainage dates back to 
the eighteenth century and is based on anatomical obser-
vations of structures composed of arachnoid cells, appro-
priately named arachnoid granulations (macroscopic) 
and arachnoid villi (microscopic). These structures pro-
ject from the subarachnoid space to the venous sinus 
within the dura and rely on hydrostatic pressure as the 
driving force for CSF movement. From here, it is unclear 
how CSF is transported into the blood; however, some 
researchers propose that this occurs through gaps in 
endothelial cells and/or pressure-dependent pinocytosis 
[89].
The majority of evidence supporting a role for arach-
noid villi is anatomical; physiological evidence of their 
role in CSF drainage is limited. Previous work has dem-
onstrated the movement of CSF through the arachnoid 
granulations in an in  vitro model; however, the exact 
pressure changes and dynamics occurring within the cra-
nial compartment are difficult to replicate [90].
The appearance of tracer in peripherally circulating 
plasma following injection into the CSF space suggested 
that the arachnoid granulations were involved in the 
transport of CSF across the arachnoid villi [91]. Further, 
when aiming to investigate the relative contribution of 
extracranial lymphatic drainage, another hypothesis of 
CSF drainage, Boulton et  al. monitored tracer content 
in plasma following cervical lymphatic ligation. Their 
observations led them to the conclusion that the arach-
noid villi and cervical lymphatics contributed equally 
to the clearance of tracer. Additional studies have also 
implicated the spinal canal in CSF clearance [17]. These 
observations show that the contribution of the peripheral 
lymphatic system in tracer transport into plasma must be 
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considered when using tracers to investigate the role of 
arachnoid villi in CSF clearance.
The appearance of the arachnoid villi occurs after 
birth. Developmental studies on pre-natal infants have 
observed a lack of arachnoid villi at this stage [92]. This 
suggests that alternative mechanisms of CSF drainage are 
occurring during the pre-natal stage, and it may be that 
these alternative mechanisms persist in function after 
birth. Overall, the role of arachnoid granulations in CSF 
drainage is disputed and it is likely that additional mecha-
nisms also heavily contribute.
The role of arachnoid granulations in CSF drainage 
may be a secondary mechanism. Injection of 131I-human 
serum albumin into the CSF space of sheep produced 
an increase in tracer concentration in the intracra-
nial venous sinuses (IVS), which gradually decreased as 
the concentration of tracer in peripheral venous blood 
increased (PVB). Further, in animals with a sealed cri-
briform plate, an elevation in ICP increased the ratio of 
tracer in the IVS compared to the PVB demonstrating 
increased uptake of tracer into the intracranial venous 
sinuses, presumably by the arachnoid granulations. From 
these observations, the authors proposed a combined 
model of CSF drainage in which lymphatic exit is the pri-
mary site of drainage with the recruitment of arachnoid 
projections under excessive pressure gradients [18].
Lymphatic drainage
Some of the most compelling evidence of CSF drainage 
mechanisms implicates a role for extracranial lymphat-
ics in CSF clearance. Transport of CSF to the cervical 
and spinal lymphatics are conserved across several spe-
cies. CSF flows along the space between the outer dura 
and the nervous tissue of olfactory and spinal nerves [14, 
17, 93, 94]. These observations have given new focus to 
investigations of CSF drainage, one which has encour-
aged some researchers to integrate the arachnoid villi 
hypothesis and others to move away from it completely.
The cribriform plate has been highlighted as an impor-
tant route of CSF drainage in multiple animal models [14, 
16]. Experiments carried out by Johnston’s lab explored 
the influence of blocking the cribriform plate drainage 
path on ICP in sheep. By scraping away the olfactory 
nerves and sealing the cribriform plate with glue, they 
observed an elevation in ICP that was around double that 
of animals subjected to sham surgery [14]. Additional 
studies from the same group used Evans Blue dye and 
observed accumulation in the lymphatic vessels underly-
ing the cribriform plate following infusion into the CSF 
space via the cisterna magna [93]. These observations 
indicate that transport through the cribriform plate via 
the olfactory nerves is an important mechanism of CSF 
drainage.
CSF drainage via both the spinal canal and the cribri-
form plate was also observed in spontaneously hyperten-
sive rats. Using a novel method for contrast-enhanced 
computed tomography (CT), contrast infused into the 
lateral ventricles was observed in the spinal canal within 
9.1  min and the cribriform plate within 22.2  min [17]. 
When comparing young and aged rats, it is interesting to 
note that although ICP was higher in aged animals when 
compared to young, CSF flow did not differ significantly 
between the groups. This is surprising since one study 
previously demonstrated that raised ICP increased CSF 
transport into the extracranial lymphatics [95]. However, 
ICP was elevated artificially in the latter study, while the 
former study looked at natural ICP elevation as a conse-
quence of age. This suggests a homeostatic mechanism 
for maintaining CSF drainage in aged rats or perhaps the 
similar drainage rate in aged rats and young rats despite, 
differences in ICP, is a consequence of reduced CSF 
secretion in aged rats [96].
Continuous fluid exchange
One of the most modern and controversial approaches 
to CSF dynamics abandons the concept of CSF secre-
tion, flow and drainage at specific loci within the cranial 
compartment. Instead, it proposes a consistent exchange 
of fluid between the CSF, ISF, blood and the parenchyma 
throughout the full system, driven by osmotic and hydro-
static forces [97]. This hypothesis contradicts the large 
amount of evidence available in support of the ‘classi-
cal’ and lymphatics CSF hypotheses, which demonstrate 
CSF secretion at the choroid plexus and CSF drainage 
via the arachnoid villi or extracranial lymphatics [89]. 
One of the main issues of this hypothesis is that water 
exchange between CSF, ISF and parenchyma is not nec-
essarily indicative of overall CSF movement, as water 
can move independently of the ions composing CSF. 
Therefore, water exchange and CSF exchange should be 
investigated separately. Some have aimed to combine this 
modern model with the currently accepted model of CSF 
drainage [98]; however, this viewpoint is far from being 
accepted by the majority of researchers and further evi-
dence is required for integration of this concept into our 
current understanding. Another study observed reduced 
transport of radiolabelled water (H217O) following intra-
venous administration occuring in AQP4 knockout mice 
but not in the AQP1 knockouts [99]. Overall, the authors 
of this study used this evidence to argue that CSF secre-
tion is primarily mediated by AQP4 rather than AQP1, 
therefore, suggesting that the BBB-astrocyte complex 
plays a more important role in CSF secretion when com-
pared to the choroid plexus.
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A role of ‘glymphatics’ in CSF drainage
Unlike peripheral organs, the brain does not contain 
a lymphatics system. Instead, CSF acts as a clearance 
mechanism for extracellular solutes in the CNS; the exact 
mechanisms underlying this clearance were previously 
unclear. Recently, CSF transport along perivascular tun-
nels, surrounded by astroglial cells, has been described 
and proposed as a mechanism for protein and solute 
clearance [7]. This system would support CSF and ISF 
interaction, as CSF moves from the subarachnoid space 
into the brain parenchyma along penetrating arteries 
where it can mix with ISF and drains back into the CSF 
system along a paravenous pathway. This system appears 
to be somewhat AQP4-dependent, as deletion of this 
gene in mice drastically reduces interstitial solute clear-
ance and the clearance of soluble amyloid-β from the 
CNS. The movement of CSF into the perivascular space 
of the penetrating arteries is supported by structural 
investigations with electron microscopy that revealed the 
presence of specialised pores on the adventitial lining of 
leptomeningeal vessels within the subarachnoid space—
offering a site of entry into the perivascular space [35].
In the context of neurological injury, ‘glymphatic’ 
function appears to decline. This has been reported in 
TBI [100], subarachnoid haemorrhage [101, 102] and 
ischaemic stroke [102]. This impaired function can be 
detrimental to patients following neurological injury, 
particularly as the clearance of extracellular proteins 
becomes impaired. Iliff et al. reported reduced clearance 
of amyloid-β when ‘glymphatic’ function is impaired in 
AQP4-absent mice. In 2014, the same group reported 
impaired tau clearance when ‘glymphatic’ function was 
reduced following TBI [7, 100]. This attenuation of ‘glym-
phatic’ function and protein clearance was associated 
with AQP4 distribution, which was altered post-TBI. 
Reduction in protein clearance can have significant impli-
cations, such as development or early onset of dementia 
or Alzheimer’s disease in which aggregation of these pro-
teins is reported [103].
It is worth noting that the ‘glymphatic’ hypothesis of 
protein and metabolite clearance is highly debated. The 
‘glymphatic’ hypothesis of CSF movement within the 
brain involves convective movement of CSF to clear sol-
utes, proteins and metabolites in a process dependent 
on AQP4 [7]. However, Smith et  al. [88] demonstrated 
movement of fluorescent tracers, which was dependent 
on size—indicating transport by diffusion. Further, Smith 
et al. also found that AQP4 knockout mice and rats did 
not experience any deficiency in protein transport from 
the subarachnoid space to the brain parenchyma. This 
hypothesis has also been challenged in other reviews in 
which the likelihood of convective transport through the 
brain ECS, in which there is high hydraulic resistance, has 
been questioned [31]. The perivascular, fluid filled canals 
surrounding the perforating arteries and veins in the 
brain parenchyma known as the Virchow–Robin spaces 
(VRS) allows bidirectional exchange of fluids between 
the brain ECS and the subarachnoid space. Therefore, 
the current evidence supports a perivascular fluid sys-
tem, where fluid flows via convection or dispersion along 
the perivascular spaces of arteries and diffuses through 
the neurovascular unit at the capillary level where CSF/
ISF exchange is regulated. It then drains out of the paren-
chyma via perivascular spaces of veins back to the CSF in 
the subarachnoid space and other sites, including some 
seepage across the ependymal into the ventricles. This 
allows for efficient communication between CSF pro-
duced by the choroid plexuses and the brain parenchyma.
Limitations of current studies
Experiments using protein tracers have been utilised to 
elucidate the pathways of CSF lymphatic drainage from 
the cranium; however, attention must be given to the 
tracers used to ensure that they follow a similar path 
to that of CSF. Some tracers may be recirculated from 
plasma to re-enter the lymphatics system, leading to false 
estimates regarding the extent to which the lymphatic 
system contributes to CSF drainage [89]. Additionally, 
the CSF has both an immunological role and an osmo-
larity regulatory role within the cranial compartment; 
therefore, separate transport pathways are necessary to 
control the movement of proteins and metabolites as 
well as water [3]. This is important to consider in tracer 
experiments, as the movement of water within the com-
partment is just as important as protein clearance—par-
ticularly when considering the contribution of CSF to 
elevations in ICP. Additionally, any alterations to CSF 
osmolarity throughout these experiments could increase 
water transport into the CSF space and dilute tracer con-
centrations to give a false indication of tracer transport.
CSF dynamics and ICP elevation
Changes in CSF can influence ICP. The intracranial com-
partment within the rigid, non-expandable skull is a 
closed system consisting of brain, blood and CSF of which 
the balance between cerebral blood inflow and outflow is 
essential for maintaining normal ICP. The Monro–Kel-
lie hypothesis dictates that a change in one of the brain, 
blood or CSF volume will result in the reciprocal change 
in one or both of the other two. When this is not pos-
sible, a further increase in volume will lead to an increase 
in ICP (Fig. 3) [104]. Acute ICP elevation can reduce cer-
ebral perfusion pressure (CPP), which is determined by 
subtracting ICP from the mean arterial pressure (MAP). 
A significant change in ICP can lead to changes in brain 
perfusion which can alter CPP when autoregulation of 
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cerebral blood vessels is impaired (e.g. during stroke), 
and chronic conditions of elevated ICP can produce pap-
illary oedema, loss of vision and death [2, 105]. The nor-
mal range of ICP in healthy adults is around 5–15 mmHg 
with increases to 30 mmHg considered pathological, and 
40 mmHg life threatening [106]. Current mechanisms of 
mitigating elevations in ICP often involve invasive surgi-
cal intervention. Therefore, investigations of approaches 
to pharmacologically attenuate these elevations are in 
high demand [2].
Increased intracranial pressure is reported as a symp-
tom or complication in several CNS pathologies like 
hydrocephalus [2, 107], IIH [108–110], TBI [111], intrac-
erebral haemorrhage (ICH) [112], subarachnoid haemor-
rhage  (SAH) [26, 113, 114], and ischaemic stroke [115, 
116]. A comprehensive review of altered CSF dynam-
ics in each of these CNS disorders would be beneficial; 
however, the depth required is outside the scope of this 
review. Instead, this section will briefly outline CSF 
dynamics in CNS disorders with an extended focus on 
literature regarding altered CSF dynamics in the context 
of ischaemic stroke and SAH to reflect the research inter-
ests of the authors.
Hydrocephalus
Hydrocephalus occurs as a result of several congenital 
and idiopathic conditions characterised by increased fluid 
accumulation in the brain and swollen ventricles. Hydro-
cephalus is caused by disruptions to CSF secretion, flow, 
or drainage, which lead to increased ICP [2]. Around 95% 
of hydrocephalus is thought to be caused by disruptions 
to CSF flow, commonly caused by tumours throughout 
the ventricular system, and there is some evidence of 
transient obstructive hydrocephalus as a complication of 
intraventricular haemorrhage [107]. Hydrocephalus may 
also be non-obstructive, in which CSF flow within the 
ventricular system is not impaired but there is decreased 
absorption. Additionally, tumours of the choroid plexus 
may also produce increased CSF secretion in rare cases 
and if this increased secretion is not compensated for by 
increased outflow, then hydrocephalus can occur [2].
Idiopathic intracranial hypertension
A similar condition to hydrocephalus, IIH, describes 
elevated ICP but without concurrent lesions or CSF dis-
ruptions. The incidence of IIH varies worldwide with 
an estimated incidence of 0.03–2.2 per 100,000, and 
recent evidence has identified obesity as a major risk 
factor [108]. The primary treatment of IIH is acetazola-
mide, which, as discussed above, is a carbonic anhydrase 
inhibitor capable of reducing CSF secretion. This clinical 
use of the acetazolamide cleverly targets CSF secretion 
to decrease the pathological elevation in ICP. However, 
this seems to be a case of targeting the symptom rather 
than the cause, and often patients are referred for a ven-
tricular or lumbar CSF shunt [109]. Further, the use of 
acetazolamide to mitigate the symptoms of IIH may be 
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Page 11 of 18Bothwell et al. Fluids Barriers CNS            (2019) 16:9 
detrimental in other aspects of CNS health, since CSF 
has roles in protein and metabolite clearance [110].
Traumatic brain injury
Patients suffering TBI often develop oedema, which 
increases ICP and impairs tissue perfusion. Studies have 
implicated the role of aquaporins in the oedema devel-
opment in cases of TBI, and upregulation of AQP4 and 
AQP9 is observed across the whole brain in experimen-
tal animal models [111]. Interestingly, the upregulation 
of AQP4 and AQP9 correlates with levels of hypoxia 
inducible factor 1α (HIF-1α), and targeted post-transla-
tional down-regulation of HIF-1α by 2-methoxyestradiol 
reverses the aquaporin upregulation. This demonstrates 
that in TBI, aquaporin upregulation can be attributed 
to hypoxia, and is relevant in other conditions of CNS 
injury, like ischemic stroke, in which hypoxia and oedema 
also occur.
The result of increased vascular permeability associ-
ated with BBB disruption, (or vasogenic oedema) is the 
paracellular leakage of protein and ion rich fluid into the 
brain. This can lead to a number of complications after 
TBI. (1) The increase in ICP from fluid accumulation 
will cause the intracranial/oncotic pressure to overcome 
vascular pressure causing blood vessels to collapse and 
nutrient flow to stop [117]. The first step of this patholog-
ical sequela only reduces venous flow, but under condi-
tion where ICP ≥ arterial blood pressure, ischemic events 
occur. (2) Excess extracellular ions and neurotransmitters 
from the leaky vessels will disrupt the delicate neuronal 
and glial homeostatic mechanisms which may result in 
acute post-traumatic seizures. (3) Immunoglobulins, 
immune cells and inflammatory mediators normally 
kept out of the immunologically privileged brain now 
have access to nervous tissue [118]. Conversely, proteins 
normally sequestered in the brain will then have access 
to peripheral circulation and tissues [119, 120]. (4) BBB 
disruption following TBI may prohibit adequate treat-
ment of elevated intracranial pressures with osmotic 
agents (e.g. mannitol or hypertonic saline) as the gradi-
ent which would normally drive water out of the brain 
might be impaired. There are some recent preclinical 
studies indicating that modulation of the BBB using small 
inhibitory RNA directed against claudin-5 may markedly 
improve the outcome of patients with cerebral oedema 
[121]. Signs of cytotoxic oedema, like cellular swelling, 
can be induced in as soon as 30 min following ischaemia, 
hypoxia and structural injuries. Changes in osmotic bal-
ance between the intracellular compartment and the ECS 
occur as a result of this cytotoxic oedema. This imbalance 
leads to increased cell volume and a 16% decrease [122] in 
the volume of ECS. This process leads to a net movement 
of water from the ECS to the intracellular compartment, 
and swelling of the brain may occur as a consequence 
of the ion gradient setup between the ECS and cerebral 
microvasculature. The gradient induced by depleted  Na+, 
water and  Cl− promotes ion and water movement across 
the BBB into the ECS causes an elevation in ICP [42]. The 
term “ionic oedema” has been assigned to this secondary 
movement of ions.
Intracerebral haemorrhage
In the case of ICH, elevations in ICP are caused by an 
increased volume entering the intracranial compart-
ment via lesion, independent of CSF. Williamson et  al. 
[112] investigated whether this elevation could be coun-
tered by targeting CSF secretion with acetazolamide in a 
collagenase-induced rat model of ICH. They found that 
ICH increased ICP in comparison to sham-control rats. 
Acetazolamide did not attenuate the average ICP in the 
ICH rats; however, it did reduce the number of tran-
sient ICP spikes—characterised by a 1-min peak with an 
increase of > 20 mmHg. Additionally, ICP was more sta-
ble in drug-treated rats—a marker of improved intracra-
nial compliance. In this example, although CSF was not 
the primary cause of the elevated pressure, it was still 
beneficial as a target in attenuating the effects of ICH 
[111]. If CSF can be targeted in this way for ICP disorders 
that are not a direct result of CSF abnormalities, then it 
can certainly be used for those in which CSF disequilib-
rium is the primary cause.
Subarachnoid haemorrhage
SAH describes a subset of stroke in which cerebral vessels 
haemorrhage into the subarachnoid space, accounting for 
around 5% of strokes [123]. Neurological injury follow-
ing SAH can be described as biphasic. Global ischaemia 
and toxicity of subarachnoid blood cause initial brain 
injury on the incidence of vessel rupture [124, 125]. 
Delayed brain injury occurs in around 30% of patients 
and describes delayed neurological deterioration caused 
by delayed cerebral ischaemia, often presenting up to 
2 weeks post-stroke [126]. The predicted long-term out-
comes of SAH are worse than that of ischaemic stroke, 
and many survivors continue to experience cognitive def-
icits, decreased quality of life, altered mood and fatigue 
even years after the incident [127]. Secondary physiologi-
cal responses to SAH can have drastic consequences on 
the survival of tissue within the brain parenchyma. There 
is significant evidence of hydrocephalus, vasospasm and 
increased ICP in response to vessel rupture [112, 113].
A recent study investigated the association between 
ICP after SAH and clinical outcomes in patients. This 
was a retrospective study of 116 patients suffering severe 
SAH, comatose as a consequence of SAH and/or present-
ing with hydrocephalus post-insult. The authors found 
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that 81% of patients experience at least one episode of 
elevated ICP (defined as ICP > 20 mmHg for 5 min), and 
36% had a ‘highest mean ICP’ of > 20  mmHg (highest 
mean ICP over a 12-h recording period). When examin-
ing the clinical implications of this high ICP, they found 
an association between high mean ICP (> 20 mmHg) and 
neurological status, rebleeding, and early lesions detected 
by CT scan [128]. This would suggest that elevated ICP 
following SAH leads to secondary degeneration and 
increased risk. However, as the study was conducted in 
patients, a causative relationship has not been tested.
Others have also reported increases in ICP following 
vessel rupture, along with hydrocephalus and vasospasm 
[112, 113, 129, 130]. A clinical study of 27 SAH patients 
found that all patients within their cohort experienced 
some degree of ICP elevation following vessel rupture 
[26]. Further, this rise in ICP had a negative influence 
on the CBF. The mechanisms driving this ICP could be 
attributed to blood entry from the ruptured vessel or 
oedema development in response to injury. Overall, the 
rise in ICP observed in patients was associated with poor 
clinical outcome; therefore, investigations of therapies to 
target this elevation in ICP are required.
The involvement of CSF in elevated ICP following SAH 
is yet to be fully defined. However, some clinical obser-
vations have reported disruptions to CSF flow associated 
with SAH [131–134], and studies of animal SAH models 
support these observations [101, 135]. Disruption of CSF 
flow along the ‘glymphatic’ pathway was shown follow-
ing SAH by comparing the distribution of tracers injected 
into the cisterna magna; this disruption was sustained 
for at least 4 days with improved distribution at 30 days 
[101]. The authors proposed that this attenuation in CSF 
flow was tissue-factor (TF) dependent; however, a causa-
tive relationship could not be determined as increased 
haemorrhaging in the presence of TF antibodies damp-
ened the fluorescent signal of the tracers. Additionally, 
ICP was increased within 1-min of SAH, reaching a max-
imum of 290% of the baseline. The elevation was reduced 
but sustained at 1-h post-stroke, at 151% of the baseline.
Increased ICP following SAH presents patients with 
additional risks and may contribute to delayed brain 
injury. Reports of impaired CSF flow following SAH pro-
vide insight into the mechanisms underlying this ICP rise 
and create new pathways for exploring therapeutic tactics 
to reduce this ICP in the hope of preventing secondary 
degeneration. One study has already examined the use 
of tissue plasminogen activator (tPA) in preserving CSF 
flow post-SAH and found that intracisternal injection of 
recombinant tPA was able to lower ICP, increase cortical 
blood volume and partially restore CSF flow 24  h after 
SAH [135]. A better understanding of CSF circulation 
and outflow pathways would further advance efforts to 
minimise deterioration after SAH.
Ischaemic stroke
ICP elevation has been demonstrated following ischae-
mic stroke in both animals and humans [114, 115, 136]. 
This elevation can have severe consequences such as 
reduced CBF, BBB disruption and altered fluid move-
ment [38]. These observations have long been associated 
with oedema development; however, oedema may not be 
the sole determinant of increased ICP.
Oedema is a known complication of ischaemic stroke, 
particularly in cases of large cerebral infarction. A higher 
degree of neurological deficit is reported in stroke 
patients presenting with oedema when compared to 
those without [137]. In some cases, this oedema requires 
medical intervention (mannitol, diuretics, corticoster-
oids, barbiturates and surgical decompression) to allevi-
ate the consequently high ICP [138]. The attenuation of 
oedema volume in a rodent model of ischaemic stroke 
improves functional outcome, which offers a potential 
target for improving symptoms in humans [139]. Human 
studies of ICP elevations following ischaemic stroke 
primarily investigate patients with large oedema, and 
because of the invasive procedures involved, the studies 
do not include patients suffering smaller strokes [140]. 
This leaves us with questions surrounding elevations in 
ICP in patients suffering smaller strokes: is oedema, in 
fact, the underlying cause; and if not, what is?
A recent study using a preclinical rodent model of 
ischaemic stroke demonstrated a transient ICP eleva-
tion approximately 24  h after ischaemic stroke [17]. 
This investigation provides evidence of ICP elevation 
after relatively minor stroke. Oedema was observed in 
the ipsilateral hemisphere of the experimental group, 
which could be prevented by therapeutic short-term 
moderate hypothermia (32.5  °C). However, volume of 
oedema could not be correlated with elevations in ICP, 
suggesting that oedema was not the only cause of ICP 
elevation in these animals [115]. This study casts doubt 
on the causative relationship of oedema and ICP that 
was previously assumed. It is highly likely that a change 
in CSF volume could be a contributing factor to these 
observations when there is no change in cerebral blood 
volume. So how might CSF secretion be altered fol-
lowing ischaemic stroke? Ischaemic stroke is a major 
stressor in the CNS and can drastically alter the physi-
ology of individual cells, tissue and fluid transport. As 
discussed above, the choroid plexus is regarded as a 
major site of CSF secretion; therefore, alterations to its 
function as an outcome of ischaemic stroke may have 
an impact on CSF secretion and consequently, ICP.
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Reduced blood supply to the lateral ventricle choroid 
plexus (LVCP) was observed in two rat models of cor-
tical ischaemic stroke: two-vessel occlusion + hypoten-
sion model; and, the commonly used, middle cerebral 
artery occlusion (MCAo) model. Ennis and Keep (2006) 
found a reduction in LVCP blood flow to 13% of con-
trol blood flow with the former model and 62% with the 
latter. They also investigated the influence of two-vessel 
occlusion + hypotension on BCSFB integrity by observ-
ing the permeability of the barrier with  [3H]-inulin 
entry into the CSF. At 6-h of reperfusion, they found 
that 10  min of occlusion doubled the BCSFB perme-
ability, while 30  min of occlusion trebled permeability 
[141]. The influence of ischaemia on BCSFB integrity 
may be significant in understanding how fluid exchange 
at the choroid plexus alters following ischaemic stroke. 
However, permeability of the BCSFB was not investi-
gated following MCAo, therefore, it is unclear if this 
model produces a significant loss of barrier integrity 
or whether drastic major occlusion is necessary for a 
noticeable difference. We do know that MCAo causes 
loss of integrity of the BBB, which can increase fluid, 
ion and lymphocyte entry into the brain [142].
Ennis and Keep [141] also noted oedema of the cho-
roid plexus after 24  h of permanent occlusion. Addi-
tional morphological studies have identified swelling of 
the choroid plexus epithelium and markers of prolifera-
tion through bromodeoxyuridine staining post-stroke 
[143]. Before that study, no morphological changes 
were identified by Nagahiro et  al. (1994) at 6-h post-
reperfusion; however, the difference in observations 
may result from the different time points observed 
[144]. Further study of morphological changes to the 
choroid plexus during and after ischaemic stroke are 
warranted and may give us more of an understanding 
of how CSF secretion is affected by ischaemia and an 
indication of how long disruptions to CSF physiology 
persist.
Recently, a nonselective cation channel has piqued 
interest within research of the choroid plexus. Preston 
et al. [145] have identified that activation of the transient 
receptor potential vanilloid 4 (TRPV4), a mechano- and 
osmotic-sensitive channel, can increase ion flux and 
conductance—a marker of permeability—in a porcine 
choroid plexus cell line. Activation of the channel allows 
 Ca2+ entry into the choroid plexus epithelial cells and 
results in activation of  Ca2+ dependent ion channels, 
specifically the  Ca+-activated intermediate conductance 
 K+ channel, KCNN4c. The authors of this study postu-
late that the channel plays a role in the regulation of CSF 
secretion.
This suggestion that TRPV4 is involved in the regula-
tion of CSF is interesting considering other groups have 
detected an upregulation of TRPV4 in the ipsilateral 
hemisphere following ischaemia which contributes to 
greater neuronal injury [146]. Some investigators have 
even targeted the TRPV4 channels in mice to success-
fully alleviate cardiac ischaemia/reperfusion injury [147]. 
Although highly expressed in choroid plexus epithelial 
cells, as far as we are aware, the expression and activity 
of TRPV4 in the choroid plexus has not been investigated 
following ischaemic stroke. Given the results presented 
by other groups, it would be an interesting path of explo-
ration—particularly considering its potential role in CSF 
secretion regulation.
The role of aquaporins in CSF secretion was 
described above, and AQP expression can be altered by 
hypoxia, ischaemia or CNS injury [110]. Interestingly, a 
recent study detected AQP4 expression in the choroid 
plexus of aged mice, which was undetectable in young 
mice [148]. They also observed an increase in ventricu-
lar size and intraventricular pressure in aged animals 
when exposed to hypoxia that was less prominent in 
young animals. This increase in ventricular size was 
absent in a homogenous AQP4 knockout model. Fur-
ther, hypoxia induced a cognitive deficit in aged wild-
type mice (novel-object recognition test), which was 
not present in aged  AQP4−/− mice. These data impli-
cate AQP4 in hypoxia-induced hydrocephalus and sub-
sequent cognitive decline, likely because of increased 
CSF secretion. Experiments using AQP knockout mice 
indicate that osmotically driven water transport fol-
lowing ischaemia or acute water intoxication (leading 
to cytotoxic oedema) is mediated by AQP4 in the pres-
ence of an intact BBB [149]. Following MCAo in mice, 
AQP4 expression has been shown to be temporar-
ily reduced or lost around 24 h post stroke during the 
reperfusion phase, and a partial recovery by 72 h post 
stroke [150]. The authors concluded that the biphasic 
change in perivascular AQP4 expression might define 
water influx subsequent to oedema at 24  h, followed 
by supporting absorption of excess fluid by 72  h. This 
suggests that perhaps reducing the expression level of 
perivascular AQP4 is the brain’s own defence mecha-
nism by which it tries to limit water influx via the water 
channels following ischaemia when BBB integrity is not 
compromised. In addition, hydrocephalus induced by 
hypoxia during ischaemic stroke would contribute to 
an overall elevation in ICP, and if increased CSF secre-
tion does in fact occur in response to hypoxia, then this 
is an important consideration in current animal mod-
els of stroke, particularly MCAo, in which occlusion 
of the anterior choroidal artery can induce a degree of 
hypoxia within the choroid plexus. Several attempts 
have been made to develop pharmacological inhibitors 
of AQP4 to reduce brain oedema following ischaemia 
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with little success [151]. Recently, Far et al. [152] have 
shown the effectiveness of two promising AQP4 inhibi-
tors following a high throughput screening of small 
molecule libraries. AER-270 and AER-271 prevented 
oedema in a mouse model of water intoxication and in 
rodent models of MCAo respectively.
Conclusions
This review summarises our current understanding of 
CSF dynamics with a focus on effects on ICP during neu-
rological diseases, and highlights some of the discrepan-
cies within the field. The implications of such findings are 
of high clinical relevance for understanding and treat-
ing neurological diseases where brain fluid homeostasis 
is impaired. Our efforts to elucidate the regulators and 
mechanisms involved in CSF secretion are still ongo-
ing. Some evidence suggests the involvement of AQP1 
at the choroid plexus [83], and more recent discoveries 
implicate the molecular transfer of water via NKCC1 in 
CSF secretion [70]; these insights may provide targets 
for therapeutic control of CSF in conditions of exces-
sive secretion and elevated ICP. Regarding CSF drain-
age, the conventional view of transport into the superior 
sagittal sinus by arachnoid projections is challenged with 
evidence of the involvement of extracranial lymphatics 
[14–18]. Other hypotheses of CSF drainage have been 
proposed but are currently criticised within the field. 
Inhibitors of CSF production, like acetazolamide, are 
widely used in clinic for lowering ICP, and animal stud-
ies have demonstrated their ability to decrease ICP in 
rats [153, 154]. However, their efficacy in humans is con-
troversial with some reporting attenuated symptoms of 
elevated ICP in IIH patients prescribed acetazolamide 
[155], and others reporting that weight loss was more 
efficacious than acetazolamide [156]. Further, a recent 
Cochrane review concluded that there is currently insuf-
ficient evidence to support or reject the clinical use of 
acetazolamide in treating symptoms of elevated ICP 
in IIH [157]. Recent evidence suggests a role for AQPs, 
TRPV4, and NKCC1 in CSF production. Determining the 
exact role of these proteins in modulating CSF dynam-
ics and the resulting influence on ICP offers potential to 
identify therapies that are of translational value. This is 
extremely important as ICP elevation can lead to second-
ary neurodegeneration after insult/injury, and in some 
cases, can even be life threatening.
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